semaglutide approved by fda US approves weight loss drug Wegovy to prevent cardiovascular events Weight-loss GLP-1 pill approved for
Description
Semaglutide and tirzepatide both reduce appetite and slow gastric emptying, but they differ in dosing, clinical weight loss averages, and side effect profiles
In the OASIS 4 trial, participants taking oral semaglutide alongside lifestyle support achieved an average weight loss of almost 17% of their body weight over 64 weeks
Theres also evidence that GLP-1s affect reward pathways in the brain
NSAIDs are known to increase the risk of stomach ulcers and bleeding
The most important thing is to stay consistent inject on the same day every week
